<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01716806</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-015</org_study_id>
    <nct_id>NCT01716806</nct_id>
  </id_info>
  <brief_title>A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)</brief_title>
  <official_title>A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, phase 2 clinical trial designed to evaluate the efficacy
      and safety of brentuximab vedotin as a single-agent (Part A) and in combination with
      dacarbazine (Part B), bendamustine (Part C), or nivolumab (Part D) in front-line therapy of
      HL in adults age 60 and above.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose of brentuximab vedotin (all parts) or through 100 days after last dose of nivolumab (Part D only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose of brentuximab vedotin (all parts) or through 100 days after last dose of nivolumab (Part D only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate (CR)</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Participants will be followed for an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Participants will be followed for an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B symptom resolution rate</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of brentuximab vedotin and metabolites</measure>
    <time_frame>Cycle 1: predose, 30 minutes, and 24, 48, 168, and 336 hours post-dose; Cycles 2 and later (through 1 month post last dose): pre-dose and 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of brentuximab vedotin antitherapeutic antibodies (ATA)</measure>
    <time_frame>Cycles 1, 2, 4, and every 4 cycles thereafter (through 1 month post last dose [Parts A, B, and C] or through 100 days post last dose of nivolumab [Part D only]): predose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of nivolumab and metabolites</measure>
    <time_frame>Cycle 1: predose, 30 minutes, and 168 and 336 hours post-dose; Cycles 2, 4, and every 4 cycles thereafter (through 1 month post last dose): pre-dose and 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nivolumab antitherapeutic antibodies (ATA)</measure>
    <time_frame>Cycles 1, 2, 4, and every 4 cycles thereafter (through 100 days post last dose of nivolumab): predose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>Brentuximab Vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brentuximab Vedotin + Dacarbazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brentuximab Vedotin + Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brentuximab Vedotin + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.8 mg/kg every 3 weeks by IV infusion</description>
    <arm_group_label>Brentuximab Vedotin</arm_group_label>
    <arm_group_label>Brentuximab Vedotin + Bendamustine</arm_group_label>
    <arm_group_label>Brentuximab Vedotin + Dacarbazine</arm_group_label>
    <arm_group_label>Brentuximab Vedotin + Nivolumab</arm_group_label>
    <other_name>Adcetris; SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine</intervention_name>
    <description>70 mg/m2 by IV infusion on Days 1 and 2 of 3-week cycle</description>
    <arm_group_label>Brentuximab Vedotin + Bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>375 mg/m2 every 3 weeks by IV infusion</description>
    <arm_group_label>Brentuximab Vedotin + Dacarbazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>3 mg/kg every 3 weeks by IV infusion</description>
    <arm_group_label>Brentuximab Vedotin + Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically-confirmed diagnosis of classical Hodgkin lymphoma

          -  Ineligible for or have declined initial conventional combination chemotherapy

          -  Measurable disease of at least 1.5 cm as documented by radiographic technique

          -  ECOG performance status less than or equal to 3

        Exclusion Criteria:

          -  Symptomatic neurologic disease compromising instrumental activities of daily living or
             requiring medication

          -  Concurrent use of other investigational agents

          -  Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not
             completed 4 weeks prior to first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abraham Fong, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melonie Hupp</last_name>
      <phone>205-975-2944</phone>
      <email>mjwest@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero-Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Donald Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Norton</last_name>
      <phone>818-748-4726</phone>
      <email>Shelley.Norton@providence.org</email>
    </contact>
    <investigator>
      <last_name>Ravi M. Shankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine McCarthy</last_name>
      <phone>626-256-4673</phone>
      <email>cmccarthy@coh.org</email>
    </contact>
    <investigator>
      <last_name>Robert Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>John Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists / Northside Hospital Cancer Institute</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duane Stallings</last_name>
      <phone>770-496-9400</phone>
      <email>duane.stallings@gacancer.com</email>
    </contact>
    <investigator>
      <last_name>Gina D'Amato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists / Advocate Lutheran General Hospital</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Leonard Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine DiSilvestre</last_name>
      <phone>301-571-2016</phone>
      <email>cdisilvestre@ccbdmd.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Hauke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Garbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center / University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Burns</last_name>
      <phone>585-273-3903</phone>
      <email>Don_Burns@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Friedberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Yasenchak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Kathryn Kolibaba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth 12th Avenue</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Robert L. Ruxer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Longview</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Matei Socoteanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Seton Williamson</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Vivian Cline-Burkhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Blacksburg</city>
        <state>Virginia</state>
        <zip>24060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Jerome Goldschmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Dipti Patel-Donnelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Scott</last_name>
      <phone>804-628-1909</phone>
      <email>jscott@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Beata Holkova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Pagel</last_name>
      <phone>206-215-1426</phone>
      <email>jpagel@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>John Pagel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 30, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2012</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Antigens, CD30</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>monomethylauristatin E</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

